Immunoglobulin G in aging and cancer
-
By
-
Matthew Bu
-
Zhongguang Li
-
Elyse Jones
-
Umme Lubaba
-
Xuefeng Liu
-
Haichang Li
-
July 3, 2026
-
Clinical Scorecard: The Role of Immunoglobulin G in Cancer and Aging Processes
At a Glance
| Category | Detail |
|---|
| Condition | Immunoglobulin G (IgG) dysregulation in cancer and aging |
| Key Mechanisms | Altered glycosylation and immune modulation by IgG |
| Target Population | Older adults and cancer patients |
| Care Setting | Immunology and oncology research |
Key Highlights
- IgG shows aberrant glycosylation in aging and cancer contexts.
- Tumor-associated IgG (T-IgG) is linked to cancer progression.
- Aging is associated with chronic low-grade inflammation (inflammageing).
- Age-associated IgG may contribute to a pro-inflammatory environment.
- IgG remodeling may serve as a link between aging and tumorigenesis.
Guideline-Based Recommendations
Diagnosis
- Investigate IgG glycosylation patterns as potential biomarkers.
Management
- Explore therapeutic strategies targeting IgG modifications.
Monitoring & Follow-up
- Assess IgG levels and glycosylation in aging and cancer patients.
Risks
- Monitor for impaired immune responses in aging populations.
Patient & Prescribing Data
Older adults and individuals with cancer
IgG modifications may influence treatment efficacy.
Clinical Best Practices
- Evaluate the role of IgG in immune dysregulation during aging.
- Consider the implications of T-IgG in tumor microenvironments.
Related Resources & Content
